Abstract Significance: The antiulcer peptide, stable gastric pentadecapeptide BPC 157 (previously employed in ulcerative colitis and multiple sclerosis trials, no reported toxicity (LD1 not achieved)), is reviewed, focusing on the particular skin wound therapy, incisional/excisional wound, deep burns, diabetic ulcers, and alkali burns, which may be generalized to the other tissues healing
In the first-ever human study on oral BPC-157, over 90% of participants experienced a reduction in painand more than 70% saw statistically significant and clinically meaningful relief on the validated PROMIS Pain Intensity metric
This dual functionality provides deeper insight into how micronutrient signaling integrates with peptide-driven biological processes
Liver Injury Is Common Among Chronic Abusers of Ketamine
*Correspondence: Ateya M
Yet if the peptide actually works, commercial entities could feasibly patent novel compounds similar to BPC-157 and cash in
